Literature DB >> 34551288

Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T cell activation.

Min Zhao1, Lijun Fu2, Yan Chai3, Meng Sun4, Yan Li3, Shuo Wang3, Jianxun Qi3, Bin Zeng5, Le Kang4, George F Gao6, Shuguang Tan7.   

Abstract

Glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR) is a critical regulatory molecule in modulation of T cell immune responses. Here we report the mouse GITR (mGITR) and mGITR ligand (mGITRL) complex structure and find that the binding interface of mGITR and mGITRL is distinct from the typical tumor necrosis factor superfamily (TNFSF)/TNF receptor superfamily (TNFRSF) members. mGITR binds to its ligand with a single domain, whereas the binding interface on mGITRL is located on the side, which is distal from conserved binding sites of TNFSF molecules. Mutational analysis reveals that the binding interface of GITR/GITRL in humans is conserved with that in the mouse. Substitution of key interacting D93-I94-V95 (DIV) in mGITR with the corresponding K93-F94-S95 (KFS) in human GITR enables cross-recognition with human GITRL and cross-activation of receptor signaling. The findings of this study substantially expand our understanding of the interaction of TNFSF/TNFRSF superfamily molecules and can benefit the future design of biologics by targeting GITR/GITRL.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GITR-GITRL complex; TNFSF/TNFRSF; atypical binding; crystal structure

Mesh:

Substances:

Year:  2021        PMID: 34551288     DOI: 10.1016/j.celrep.2021.109734

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  1 in total

1.  Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.

Authors:  Changhao He; Rachana R Maniyar; Yahel Avraham; Roberta Zappasodi; Radda Rusinova; Walter Newman; Heidi Heath; Jedd D Wolchok; Rony Dahan; Taha Merghoub; Joel R Meyerson
Journal:  Sci Adv       Date:  2022-02-25       Impact factor: 14.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.